Merck announces FDA acceptance of New Drug Application for Vorapaxar
24 July 2013 | By Merck
Merck announced that the NDA for vorapaxar, has been accepted for standard review...
List view / Grid view
News
Roche’s obinutuzumab (GA101) delayed disease progression longer than MabThera/Rituxan in people with one of the most common forms of blood cancer
24 July 2013 | By Roche
Results from the phase III CLL11 study...
Bristol-Myers Squibb partners with the Centers for Disease Control Foundation
23 July 2013 | By Bristol-Myers Squibb Company
Joint effort supports early disease identification to connect at-risk patients to necessary care...
SPS Pharma Services relocates to a new facility
23 July 2013 | By SOTAX AG
SPS Pharma Services, a worldwide leader for dissolution method development has moved to its new site in Orleans, France...
“Roche Continents” at the Salzburg Festival explores the common ground of creativity in art and science
22 July 2013 | By Roche
Roche invites 100 students from all over Europe to the Salzburg Festival...
The Apprentice’s Nick Hewer to host IChemE Awards
22 July 2013 | By IChemE
The Institution of Chemical Engineers has announced The Apprentice’s Nick Hewer to host IChemE Awards...
US and EU regulatory authorities accept PLEGRIDY™ (peginterferon beta-1a) marketing applications for review
19 July 2013 | By Biogen Idec
U.S. and EU regulatory authorities have accepted marketing applications...
Roche launches new tests for monitoring transplant patients on immunosuppressive therapy
19 July 2013 | By Roche
Tests support long-term routine management of organ transplant recipients...
Roche launches new ProGRP test for more precise diagnosis in lung cancer
18 July 2013 | By Roche
Roche announced the global launch of Elecsys ProGRP...
Gilead announces interim Phase 2 data for idelalisib showing response in refractory indolent non-Hodgkin’s lymphoma
17 July 2013 | By Gilead Sciences
Results from Phase 2 study...
Boehringer Ingelheim and EFSD announce first recipients of diabetes research funding
17 July 2013 | By Boehringer Ingelheim
BI and EFSD commit €2.5 million to help accelerate European initiatives...
Novartis announces final agreement with Dr. Daniel Vasella
17 July 2013 | By Novartis
The Novartis Board of Directors announced a final agreement with its former Chairman, Dr. Daniel Vasella.
A 3D InSight™ into drug discovery with Tecan’s Infinite® M200 PRO
A novel solution for analyzing 3D cell cultures, based on Tecan’s Infinite® M200 PRO and InSphero’s 3D InSight™ microtissue technology, is helping to reduce the cost of early phase drug development.
The Lancet Oncology publishes results of XGEVA® (denosumab)
16 July 2013 | By Amgen
Phase 2 study reports safety and efficacy results in patients with giant cell tumor of bone...
GSK issue response to China investigation
16 July 2013 | By GSK
GSK issue a statement In response to the ongoing investigations by government authorities in China...
